Skip to main content

Home/ Diseases/ Group items tagged multiple_sclerosis clinical_trial

Rss Feed Group items tagged

Matti Narkia

Vitamin D and MS: Burton - 1 views

  •  
    "Dr. Jodie Burton is the acting principal investigator (PI) of the dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis with Dr. O'Connor. She started the trial as his fellow, while doing an additional 2 years of training in MS specifically after she received her neurology certification. She completed her fellowship training in 2007. Now she is staff doing clinical research and continuing with the vitamin D trial. As of August 2009, she will be Assistant Professor in Neurology in the Department of Clinical Neuroscience in Calgary and at the University of Calgary. She will be part of the MS team there with Dr. Luanne Metz and the MS group.

    Please scroll down for an abstract of the trial:
    A Phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis."

    Conclusions:
    High-dose VD3 (~10 000 IU/day, possibly higher) in MS is safe and tolerable, with evidence of clinical improvement.
Matti Narkia

Safety of vitamin D3 in adults with multiple sclerosis -- Kimball et al. 86 (3): 645 --... - 0 views

  •  
    Safety of vitamin D3 in adults with multiple sclerosis.
    Kimball SM, Ursell MR, O'Connor P, Vieth R.
    Am J Clin Nutr. 2007 Sep;86(3):645-51.
    PMID: 17823429

    Conclusions: Patients' serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. The data support the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.
1 - 2 of 2
Showing 20 items per page